MedTrace Logo

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

NCT01462851 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2012-03-13

No results posted yet for this study

Summary

This study is designed to observe the safety and concentrations of PF-05297909 and proteins in both blood and cerebrospinal fluid after a single dose of PF-05297909 in healthy adults.

Conditions

  • Healthy

Interventions

DRUG

PF-05297909 25 mg

Single oral (PO) dose, PF-05297909 25 mg

DRUG

PF-05297909 100 mg

Single oral (PO) dose, PF-05297909 100 mg

DRUG

PF-05297909 250 mg

Single oral (PO) dose, PF-05297909 250 mg

DRUG

PF-05297909 525 mg

Single oral (PO) dose, PF-05297909 525 mg

DRUG

PF-05297909 525 mg

Single oral (PO) dose, 525 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01462851 on ClinicalTrials.gov